Add time:07/12/2019         Source:sciencedirect.com

GPR40 agonists stimulate insulin secretion only under the presence of high glucose concentration. Based on this mechanism, GPR40 agonists are believed to be promising novel insulin secretagogues with low risk of hypoglycemia. The optimizations of 3-aryl-3-ethoxypropanoic acids were performed to improve in vitro activity. We discovered compound 29r (DS-1558), (3S)-3-ethoxy-3-(4-{[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy}phenyl)propanoic acid, which was confirmed to have an enhancing effect on glucose-dependent insulin secretion after intravenous glucose injection in SD rats.

We also recommend Trading Suppliers and Manufacturers of N-{2-[(4-chlorobenzyl)oxy]benzyl}-N-(3-ethoxypropyl)amine (cas 774547-14-7). Pls Click Website Link as below: cas 774547-14-7 suppliers